Table 1 Baseline characteristics of the analyzed samples.
From: Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas
Pt | Gender | Dg | Subtype | Disease status | Sample origin | WES | Therapy | PDX |
|---|---|---|---|---|---|---|---|---|
1 | F | DLBCL | non-GC | Dg | LN | Yes | Untreated | VFN-D3 |
2 | M | DLBCL | non-GC | Dg | LN | Yes | Untreated | VFN-D6 |
3 | M | DLBCL | non-GC | R/R | LN | Yes | G-CHOP | VFN-D1 |
4 | M | DLBCL | GC | R/R | EN (soft tissues) | Yes | R-CHOP + venetoclax; R-ESHAP; R-GIFOX; RT | VFN-D4 |
5 | F | DLBCL | non-GC | R/R | LN | Yes | R-CHOP; R-ESHAP; R-GIFOX; RT | VFN-D5 |
6 | M | tDLBCL | GC, transformed from MZL | Dg | LN | No | R-COP | VFN-D12 |
7 | F | DLBCL | double-hit | R/R | LN | Yes | R-CHOP / R-ESHAP | VFN-D20 |
8 | M | Burkitt | R/R | EN (stomach) | Yes | R-Hyper-CVAD, R-MTX-HD-araC | VFN-B3 | |
9 | M | MCL | R/R | LN | Yes | Nordic protocol | VFN-M5R1 | |
10 | F | MCL | R/R | LN | Yes | Nordic protocol | VFN-M1 | |
11 | M | AITL | R/R | LN | Yes | CHOEP | VFN-T3 | |
12 | F | AITL | R/R | LN | No | Untreated | VFN-T7 | |
13 | F | PTCL, NOS | R/R | LN | Yes | CHOEP | VFN-T6 | |
14 | M | ALCL | ALK-negative | Dg | LN | Yes | Untreated | VFN-T5 |
15 | M | ALCL | ALK-positive | Dg | LN | Yes | Untreated | VFN-T4 |
